These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 3898370)
1. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Ofosu FA; Fernandez F; Gauthier D; Buchanan MR Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370 [No Abstract] [Full Text] [Related]
2. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
3. Activation of heparin cofactor II by heparin and dermatan sulfate. Tollefsen DM Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014 [TBL] [Abstract][Full Text] [Related]
4. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. Scully MF; Ellis V; Seno N; Kakkar VV Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851 [TBL] [Abstract][Full Text] [Related]
5. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790 [TBL] [Abstract][Full Text] [Related]
6. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872 [TBL] [Abstract][Full Text] [Related]
7. [Dermatan sulfate and the prevention of experimental venous thrombosis]. Desnoyers P; Bara L; Samama M Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. Ofosu FA; Fareed J; Smith LM; Anvari N; Hoppensteadt D; Blajchman MA Eur J Biochem; 1992 Jan; 203(1-2):121-5. PubMed ID: 1730217 [TBL] [Abstract][Full Text] [Related]
10. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate. Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate. Sié P; Fernandez F; Caranobe C; Gabaig AM; Boneu B Thromb Res; 1984 Jul; 35(2):231-6. PubMed ID: 6206589 [No Abstract] [Full Text] [Related]
13. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Van Ryn-McKenna J; Gray E; Weber E; Ofosu FA; Buchanan MR Thromb Haemost; 1989 Feb; 61(1):7-9. PubMed ID: 2473537 [TBL] [Abstract][Full Text] [Related]
14. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II. Yamagishi R; Koide T; Sakuragawa N FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist. Buchanan MR; Brister SJ Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347 [TBL] [Abstract][Full Text] [Related]
16. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Merton RE; Thomas DP Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466 [TBL] [Abstract][Full Text] [Related]
18. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283 [TBL] [Abstract][Full Text] [Related]
19. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Buchanan MR; Boneu B; Ofosu F; Hirsh J Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047 [TBL] [Abstract][Full Text] [Related]
20. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP; Bernat A; Gaich C; Herbert M Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]